This content is from: Corner Office Bayer’s Monsanto Deal Highlights Genetic Engineering Opportunities German pharmaceuticals giant Bayer’s $66 billion acquisition of Monsanto is about more than just seeds. By Kaitlin Ugolik September 14, 2016
This content is from: Portfolio The Morning Brief: Paulson Takes Stake in Monsanto Target Syngenta By Amanda Cantrell July 17, 2015
This content is from: Portfolio Daily Agenda: Fed Confirms June Hike on the Table Markets sell off on release of FOMC notes; Bayer makes Monsanto bid official; more corruption allegations for Malaysian fund; Wal-Mart beats estmates. By Andrew Barber May 19, 2016
This content is from: Research The 2013 All-America Research Team: Chemicals, No. 2: Vincent Andrews III Leapfrogging from runner-up to second place is Morgan Stanley’s Vincent Andrews III. October 08, 2013
This content is from: Portfolio Daily Agenda: Greek Aid Approved EU and IMF agree to release funds, relieve Greek debt; Monsanto rejects Bayer offer but courtship continues; SEC probes Alibaba; PBOC lowers yuan peg; Tiffany results bad news for luxury market. By Andrew Barber May 25, 2016
This content is from: Portfolio Daily Agenda: Investors Gauge Political Risks Trump gets bump in the polls; Bayer’s Monsanto bid is official; Japanese exports contract; fertilizer deal dies on inveresion concerns. By Andrew Barber May 23, 2016
